Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2026-08-20 21:00:05 ET · period of report 2026-08-18 · accession 0001193125-26-359676 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-20 21:00 | 2026-08-18 | AMLX | Bedrosian Camille L | Chief Medical Off | A - Grant | $0.00 | +22.8K | 288.1K | +9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-18 | A | A | 22,807 | $0.00 | 288,092 | D | — | — | (F1) The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026. |